 one drugs chronically over a very long period of time we don't really have data yet so i think that uh investors are right to be nervous i feel like this is uh pretty much overblown given the evidence that we have all right coming up after the break we've got a down outlook on two huge brands in retail stay right here you're listening to motley fool money